Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves new Claritin label

This article was originally published in The Tan Sheet

Executive Summary

FDA will allow Schering-Plough to communicate on its product label that Claritin relieves both indoor and outdoor allergies, potentially extending the OTC non-drowsy allergy medicine's benefits beyond seasonal allergy treatment. Previously, labels could only state that Claritin relieves outdoor allergies, S-P says Jan. 22...

You may also be interested in...



Claritin label change

FDA approves Schering-Plough's request to add the descriptor "Indoor & Outdoor Allergies" to the principal display panel of 10- and 30-count carton labels of Claritin Liqui-Gels (loratadine 10 mg), according to an April 6 letter. The change could extend the medicine's benefits beyond seasonal allergies. FDA approved a similar change to Claritin packaging in 2008 (1"The Tan Sheet" Jan. 28, 2008, In Brief)

QUOTED. 7 April 2020. Surendar Magar.

California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.

EMA's Decision On Ranitidine Remaining Available Could Come At End Of April

Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.

Topics

UsernamePublicRestriction

Register

PS101296

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel